Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2017 | Changing treatment landscapes, new challenges for hemonc pharmacists

Susannah Koontz Webb • 6 Oct 2017
BOPA 2017
General

How is the role of the pharmacist changing as treatments in hematological cancers develop? Susannah Koontz Webb, PharmD, BCOP, FHOP, President of the Hematology Oncology Pharmacy Association (HOPA) discusses the treatment advances in blood cancers, and how the movement towards more targeted therapies means that patients can received tailored treatments and can receive more medications in an outpatient setting. These developments create new roles and challenges for pharmacists, making it an exciting time in the field. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Susannah Koontz Webb

7:36
What is HOPA doing for pharmacists and cancer patients
Susannah Koontz Webb • 6 Oct 2017
4:09
When BOPA met HOPA: collaborations in oncology pharmacy
Susannah Koontz Webb • 6 Oct 2017

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals